| 1 |
NCT03462680 |
Recruiting |
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures |
|
- Dietary Supplement: niacin
- Other: placebo
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Unified Parkinson's Disease Rating Scale (UPDRS) change
- Mini-Mental State Examination (MMSE) change
- Stroop test change
- (and 4 more...)
|
80 |
All |
35 Years and older (Adult, Older Adult) |
NCT03462680 |
N1613-I |
|
September 28, 2016 |
September 30, 2019 |
September 30, 2019 |
March 12, 2018 |
March 13, 2018 |
|
- Charlie Norwood VA Medical Center, Augusta, GA
Augusta, Georgia, United States
|
|
| 2 |
NCT03260166 |
Recruiting |
Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus |
- Cutaneous Lupus Erythematosus
- Systemic Lupus Erythematosus Rash
|
|
Interventional
|
Phase 2 |
- Second Xiangya Hospital of Central South University
- National Natural Science Foundation of China
- Hunan Provincial Natural Science Foundation of China
- National Key Clinical Specialty Construction Project of China
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- A change in Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI) activity score
- A change in RCLASI activity score
- Response Rate and Remarkable Response Rate at 1, 2, 3, 4, and 6 months, respectively
- (and 11 more...)
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03260166 |
PFK201707 |
|
August 31, 2017 |
August 2018 |
February 2019 |
August 24, 2017 |
September 25, 2017 |
|
- The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
|
|
| 3 |
NCT01984073 |
Recruiting |
Effects of Niacin On Fatty Acid Trapping |
|
- Drug: ER Niacin Oral Fat Challenge
- Drug: IR Niacin Oral Fat Challenge
- Other: Placebo Oral Fat Challenge
|
Interventional
|
Phase 1 |
- University of Pennsylvania
- National Heart, Lung, and Blood Institute (NHLBI)
- Arizona Pharmaceuticals Inc.
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
|
20 |
All |
22 Years to 75 Years (Adult, Older Adult) |
NCT01984073 |
NOFAT
K23HL091130 |
NOFAT |
December 2012 |
October 2018 |
October 2018 |
November 14, 2013 |
May 1, 2017 |
|
- Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States - Presbyterian Hospital
Philadelphia, Pennsylvania, United States
|
|
| 4 |
NCT03432871 |
Recruiting |
Nicotinamide Riboside and Mitochondrial Biogenesis |
- Mitochondrial Diseases
- Mitochondrial Myopathies
- Progressive External Ophthalmoplegia
- (and 6 more...)
|
- Dietary Supplement: Nicotinamide Riboside
|
Interventional
|
Not Applicable |
- Cambridge University Hospitals NHS Foundation Trust
- University of Cambridge
- MRC Mitochondrial Biology Unit
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Bioavailability
- Safety - Incidence of treatment related adverse events
- Safety - change in blood analytes
- (and 10 more...)
|
15 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03432871 |
A094351 |
|
December 8, 2017 |
December 31, 2018 |
May 30, 2019 |
February 14, 2018 |
March 16, 2018 |
|
- Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
|
|
| 5 |
NCT02322203 |
Recruiting |
Effects of Niacin Therapy on Lipoprotein Composition and Function |
|
- Dietary Supplement: Niacin Extended Release
|
Interventional
|
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Changes in protein or lipid composition of any lipoprotein fraction and changes in vascular compliance as measured by CAVI
|
200 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02322203 |
150042
15-H-0042 |
|
December 20, 2014 |
April 7, 2019 |
July 3, 2019 |
December 23, 2014 |
July 16, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 6 |
NCT03419364 |
Recruiting |
Study of Nicotinamide in Early Onset Preeclampsia |
|
|
Interventional
|
Phase 2 |
- University of North Carolina, Chapel Hill
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Mean Arterial blood Pressure (MAP)
- Number of participants with alanine aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)
- Number of participants with aspartate aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)
- (and 7 more...)
|
25 |
Female |
18 Years to 55 Years (Adult) |
NCT03419364 |
17-0693
1R03HD092370-01 |
|
November 1, 2017 |
December 31, 2019 |
December 31, 2019 |
February 1, 2018 |
February 1, 2018 |
|
- UNC at Chapel Hill
Chapel Hill, North Carolina, United States
|
|
| 7 |
NCT03061474 |
Recruiting |
Nicotinamide as an Early Alzheimer's Disease Treatment |
- Alzheimer's Disease
- Mild Cognitive Impairment
|
- Drug: Nicotinamide
- Drug: Placebo Comparator
|
Interventional
|
Phase 2 |
- University of California, Irvine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in p-tau 231
- Change in p-tau 181
- Change in total tau
|
48 |
All |
50 Years and older (Adult, Older Adult) |
NCT03061474 |
20163246 |
NEAT |
July 12, 2017 |
February 28, 2019 |
February 28, 2019 |
February 23, 2017 |
February 15, 2018 |
|
- University of California, Irvine
Irvine, California, United States - University of California, Los Angeles
Los Angeles, California, United States
|
|
| 8 |
NCT03501433 |
Recruiting |
Effects of Nicotinamide Riboside on Metabolism and Vascular Function |
|
- Dietary Supplement: Nicotinamide riboside chloride (Niagen)
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- NAD+
- Vasodilatory responsiveness
- Lipdemia
- Oxidative stress and inflammation
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03501433 |
17-603 |
|
February 1, 2018 |
December 2018 |
December 2018 |
April 18, 2018 |
April 18, 2018 |
|
- Iowa State University
Ames, Iowa, United States
|
|
| 9 |
NCT03163576 |
Not yet recruiting |
The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis |
|
- Drug: Niacin
- Drug: Phosphate Binder
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the level of phosphorous level in haemodialysis patients treated by niacin
|
150 |
All |
18 Years to 60 Years (Adult) |
NCT03163576 |
ENPD |
|
June 2017 |
June 2019 |
December 2019 |
May 23, 2017 |
May 23, 2017 |
|
|
|
| 10 |
NCT03423342 |
Recruiting |
Nicotinamide Riboside in Systolic Heart Failure |
|
- Dietary Supplement: nicotinamide riboside
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- University of Washington
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
- Effect of NR on Whole Blood NAD+ Levels
- Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
- Effect of NR on Mitochondrial Function
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03423342 |
STUDY00001830
1R21HL126209-01 |
|
May 19, 2016 |
May 1, 2018 |
June 30, 2018 |
February 6, 2018 |
February 6, 2018 |
|
- University of Washington
Seattle, Washington, United States
|
|
| 11 |
NCT03562468 |
Recruiting |
A Study by ChromaDex to Assess the Effects of Nicotinamide Riboside on Cognitive Function, Mood and Sleep in Older Adults |
- Cognitive Function
- Mood
- Sleep
|
- Dietary Supplement: 300 mg/day of nicotinamide riboside
- Dietary Supplement: 1000 mg/day of nicotinamide riboside
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- ChromaDex, Inc.
- Midwest Center for Metabolic and Cardiovascular Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- The primary outcome variable will be the difference between the 300 mg NR condition and placebo in the change from baseline in executive function measured with the CNS Vital Signs test battery.
|
40 |
All |
55 Years and older (Adult, Older Adult) |
NCT03562468 |
MB-1801 |
|
June 2018 |
March 2019 |
March 2019 |
June 19, 2018 |
June 26, 2018 |
|
- MB Clinical Research
Boca Raton, Florida, United States
|
|
| 12 |
NCT03151707 |
Recruiting |
The Effects of Nicotinamide Riboside Supplementation on NAD+/NADH Ratio and Bioenergetics |
|
- Drug: Nicotinamide Riboside
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline to the end of treatment in brain NAD+/NADH ratio
- Change from baseline to the end of treatment in brain phosphocreatine (PCr) to adenosine triphosphate (ATP) ratio (PCr/ATP)
- Change from baseline to the end of treatment in creatine kinase (CK) enzyme rate
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03151707 |
2017P000006 |
|
October 1, 2017 |
July 2019 |
July 2019 |
May 12, 2017 |
July 11, 2018 |
|
- Cagri Yuksel
Belmont, Massachusetts, United States
|
|
| 13 |
NCT02416739 |
Recruiting |
Anticancer Activity of Nicotinamide on Lung Cancer |
- Non-Small-Cell Lung Carcinoma
|
|
Interventional
|
Phase 2
Phase 3 |
- Il Yeong Park, Ph.D.
- Chungbuk National University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Hazard ratio (PFS) of the nicotinamide arm to the placebo arm
- Response rate
- Difference in quality of life between the nicotinamide arm and the placebo arm
- Overall survival
|
110 |
All |
18 Years and older (Adult, Older Adult) |
NCT02416739 |
Amina-X-002 |
|
March 2015 |
February 2019 |
February 2019 |
April 15, 2015 |
July 18, 2018 |
|
- Chonnam National University Hwasun Hospital
Hwasun, Chonnam, Korea, Republic of
|
|
| 14 |
NCT03356483 |
Not yet recruiting |
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. |
- Obsessive-Compulsive Disorder
|
- Drug: Psilocybin (0.25mg/kg)
- Drug: Niacin (250mg)
|
Interventional
|
Phase 2 |
- Yale University
- Heffter Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in severity of OCD symptoms, which will be measured by The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). The Primary Outcome Measure will be collected at baseline and 48 hours, assessing change from baseline at 48 hours.
- Acute Yale-Brown Obsessive-Compulsive Scale (A-YBOCS)
- Changes in brain connectivity, which will be measured with functional Magnetic Imaging Resonance (fMRI).
- (and 21 more...)
|
30 |
All |
21 Years to 55 Years (Adult) |
NCT03356483 |
2000020355 |
|
October 2, 2018 |
January 2022 |
July 2022 |
November 29, 2017 |
July 4, 2018 |
|
- Connecticut Mental Health Center
New Haven, Connecticut, United States
|
|
| 15 |
NCT03568968 |
Not yet recruiting
New |
A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study |
|
- Dietary Supplement: Nicotinamide Riboside
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Haukeland University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease rating Scale)
- NAD metabolism
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03568968 |
2018/597 |
|
October 1, 2018 |
October 1, 2020 |
October 1, 2021 |
June 25, 2018 |
June 25, 2018 |
|
|
|
| 16 |
NCT02950441 |
Recruiting |
Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype |
|
- Dietary Supplement: Nicotinamide Riboside
- Other: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mitochondrial function assessment in skeletal muscle using high resolution respirometry
- Skeletal muscle NAD+ levels in vastus lateralis biopsy using targeted metabolomics
- Improvement in response to oral glucose tolerance test/HOMA-IR
- (and 6 more...)
|
12 |
Male |
70 Years to 80 Years (Older Adult) |
NCT02950441 |
RG_15-152 |
NADMet |
June 2016 |
September 2018 |
September 2019 |
November 1, 2016 |
June 7, 2017 |
|
- University Hospitals Birmingham NHS Foundation Trust
Birmingham, West Midlands, United Kingdom
|
|
| 17 |
NCT02835664 |
Recruiting |
Nicotinamide Riboside and Metabolic Health |
- Obesity
- Insulin Resistance
|
- Dietary Supplement: Nicotinamide Riboside (Niagen)
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Maastricht University Medical Center
- Dutch Heart Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Insulin sensitivity: muscle- and liver specific
- Muscle mitochondrial function (ex vivo)
- Ectopic lipid accumulation
- (and 5 more...)
|
15 |
All |
45 Years to 65 Years (Adult, Older Adult) |
NCT02835664 |
NL58119.068.16 |
|
December 2016 |
December 2018 |
December 2018 |
July 18, 2016 |
April 6, 2018 |
|
- Maastricht University Medical Centre
Maastricht, Netherlands
|
|
| 18 |
NCT02109614 |
Recruiting |
Early Aortic Valve Lipoprotein(a) Lowering Trial |
- Aortic Stenosis and Lipoprotein(a) Levels
|
- Drug: Extended release Niacin
- Drug: Placebo Comparator
|
Interventional
|
Early Phase 1 |
- George Thanassoulis
- Jewish General Hospital
- Laval University
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Calcium score progression by cardiac CT in individuals randomized to niacin as compared to those randomized to placebo
- Mean change in Lp(a) levels between treatment arms
|
238 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT02109614 |
A00-M105-13A |
EAVaLL |
May 2014 |
January 2017 |
September 2017 |
April 10, 2014 |
September 13, 2016 |
|
- MUHC - Montreal General Hospital
Montreal, Quebec, Canada - MUHC - Royal Victoria Hospital
Montreal, Quebec, Canada - Jewish General Hospital
Montreal, Quebec, Canada
|
|
| 19 |
NCT02812238 |
Recruiting |
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity |
- Atherosclerosis
- Diabetes
- Coronary Artery Disease
|
- Dietary Supplement: Nicotinamide riboside (NR)
- Other: Placebo
|
Interventional
|
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- The refeeding IL-1 secretion in response to inflammasome stimulation in the NR treatment arm versus the same subject's response on the placebo treatment arm using paired t-test analyses
|
42 |
All |
18 Years to 39 Years (Adult) |
NCT02812238 |
160129
16-H-0129 |
|
June 23, 2016 |
March 5, 2019 |
March 5, 2019 |
June 24, 2016 |
June 27, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 20 |
NCT03579693 |
Not yet recruiting
New |
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease |
- Chronic Kidney Disease
- Sarcopenia
- Frailty
|
- Dietary Supplement: CoQ10
- Dietary Supplement: Nicotinamide riboside
- Dietary Supplement: Placebo
|
Interventional
|
Phase 2 |
- University of Washington
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Maximal Aerobic Capacity- CoQ10
- Maximal Aerobic Capacity- NR
- Maximal Aerobic Capacity- Placebo
- (and 33 more...)
|
30 |
All |
30 Years to 79 Years (Adult, Older Adult) |
NCT03579693 |
STUDY00004998
R01DK101509 |
CoNR |
August 2018 |
January 2020 |
April 2020 |
July 6, 2018 |
July 10, 2018 |
|
- University of Washington
Seattle, Washington, United States
|
|
| 21 |
NCT02702492 |
Recruiting |
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) |
|
- Drug: KPT-9274
- Drug: KPT-9274 & Niacin ER
|
Interventional
|
Phase 1 |
- Karyopharm Therapeutics Inc
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
175 |
All |
18 Years and older (Adult, Older Adult) |
NCT02702492 |
KCP-9274-901 |
PANAMA |
June 2016 |
June 2019 |
November 2019 |
March 8, 2016 |
May 3, 2018 |
|
- University of Colorado Cancer Center
Aurora, Colorado, United States - Georgetown University, Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States - Mayo Clinic Rochester
Rochester, Minnesota, United States - (and 4 more...)
|
|
| 22 |
NCT03540758 |
Recruiting |
Regulation of Endogenous Glucose Production by Central KATP Channels |
- Type 2 Diabetes Mellitus
- Glucose Metabolism Disorders
- Glucose, High Blood
|
- Drug: Diazoxide
- Drug: Nicotinic acid
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Albert Einstein College of Medicine, Inc.
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Endogenous glucose production (EGP)
|
45 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03540758 |
2018-9039
R01DK069861 |
|
June 2018 |
November 2020 |
November 2021 |
May 30, 2018 |
May 31, 2018 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States
|
|
| 23 |
NCT02942888 |
Recruiting |
The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition |
- Mild Cognitive Impairment
- NAD
|
- Dietary Supplement: Nicotinamide riboside
- Dietary Supplement: Sugar Pill
|
Interventional
|
Not Applicable |
- The University of Texas Health Science Center at San Antonio
- University of Texas
- South Texas Veterans Health Care System
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- Change in Cognitive Assessment - Montreal Cognitive Assessment (MoCA) - from baseline at 10 weeks
- Change in cerebral blood flow from baseline at 10 weeks
- Change in plasma NAD from baseline at 10 weeks
- (and 9 more...)
|
26 |
All |
65 Years and older (Older Adult) |
NCT02942888 |
HSC20160350H |
NAD |
November 30, 2017 |
December 2018 |
December 2018 |
October 24, 2016 |
January 9, 2018 |
|
- South Texas Veterans Healthcare System (STVHCS)
San Antonio, Texas, United States - University of Texas Health San Antonio
San Antonio, Texas, United States
|
|
| 24 |
NCT02721537 |
Recruiting |
Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Athletes |
|
- Dietary Supplement: Nicotinamide Riboside
- Other: Matching placebo
|
Interventional
|
Not Applicable |
- Mayo Clinic
- University of Minnesota - Clinical and Translational Science Institute
- Thorne Research Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Screening
|
- Change in brain NAD+ levels
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT02721537 |
15-006870 |
TRMC-004 |
September 2016 |
December 2018 |
June 2019 |
March 29, 2016 |
February 23, 2018 |
|
- University of Minnesota Center for Magnetic Resonance Research
Minneapolis, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 25 |
NCT03176628 |
Recruiting |
Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study |
|
- Dietary Supplement: Basis
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- Elysium Health
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Maximum plasma concentration [Cmax] of NR
- Maximum plasma concentration [Cmax] of pterostilbene
- Area Under the Curve [AUC] of NR
- (and 6 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03176628 |
2017P000908 |
BAKIS |
November 1, 2017 |
October 31, 2018 |
October 31, 2018 |
June 5, 2017 |
March 27, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 26 |
NCT02808182 |
Recruiting |
Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D) |
- Impaired Glucose Tolerance
|
- Drug: Nicotinic acid
- Other: [7,7,8,8-2H]-palmitate
- Other: [U-13C]-palmitate
- (and 2 more...)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Plasma NEFA appearance rate
- Cardiac uptake
- WAT spillover NEFA appearance rates
- (and 9 more...)
|
40 |
All |
45 Years to 65 Years (Adult, Older Adult) |
NCT02808182 |
2016-1196 |
AGL11 |
January 17, 2017 |
May 2018 |
February 2019 |
June 21, 2016 |
February 7, 2017 |
|
- centre de recherche du CHUS
Sherbrooke, Quebec, Canada
|
|
| 27 |
NCT03151239 |
Recruiting |
Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function |
- Glucose Metabolism Disorders
|
- Dietary Supplement: NMN supplement
- Other: Placebo
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- To determine change in insulin sensitivity.
- To determine change in beta-cell function.
|
50 |
Female |
55 Years to 75 Years (Adult, Older Adult) |
NCT03151239 |
201701096 |
NMN |
July 1, 2017 |
June 1, 2019 |
June 1, 2020 |
May 12, 2017 |
May 2, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 28 |
NCT03268902 |
Recruiting |
Early Life Interventions for Childhood Growth and Development In Tanzania |
- Malnutrition
- Stunting
- Cognitive Development
- Enteric Pathogens
|
- Drug: Azithromycin Oral Liquid Product
- Drug: Nitazoxanide Oral Suspension
- Dietary Supplement: Nicotinamide
- Drug: Placebos
|
Interventional
|
Phase 2
Phase 3 |
- Haydom Lutheran Hospital
- University of Virginia
- Bill and Melinda Gates Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Height-for-age z-score (HAZ) at 18 months
- Weight-for-age z-score (WAZ) at 18 months
- Head circumference-for-age z-score (HCAZ) at 18 months
- (and 16 more...)
|
1188 |
All |
up to 14 Days (Child) |
NCT03268902 |
19465 |
ELICIT |
September 5, 2017 |
September 2020 |
December 2020 |
August 31, 2017 |
September 12, 2017 |
|
- Haydom Lutheran Hospital
Haydom, Manyara, Tanzania
|
|
| 29 |
NCT03482167 |
Not yet recruiting |
NAD+ Therapy for Improving Memory and Cerebrovascular Function in Patients With MCI |
- Mild Cognitive Impairment
|
- Drug: Niagen®
- Other: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- University of Delaware
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in cognitive scores at 12 weeks
- Change from baseline in cerebrovascular reactivity at 12 weeks
- Change from baseline in total brain blood flow at 12 weeks
- (and 2 more...)
|
58 |
All |
60 Years to 90 Years (Adult, Older Adult) |
NCT03482167 |
1079271-1
K01AG054731 |
|
June 2018 |
March 2022 |
March 2022 |
March 29, 2018 |
March 29, 2018 |
|
- Neurovascular Aging Laboratory
Newark, Delaware, United States
|
|
| 30 |
NCT03565328 |
Not yet recruiting
New |
The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects |
|
- Dietary Supplement: Niagen
|
Interventional
|
Phase 2 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- NR enhancement of mitochondrial function in skeletal muscle
- effects of NR on oxidative phosphorylation and inflammation in respective subject primary skin fibroblasts
- quantitative serum cytokine immunoassay profiling to assess whether NR blunts HF linked inflammation
- (and 2 more...)
|
50 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03565328 |
180107
18-H-0107 |
|
July 24, 2018 |
June 1, 2021 |
June 1, 2021 |
June 21, 2018 |
July 19, 2018 |
|
- Walter Reed National Military Medical Center
Bethesda, Maryland, United States - National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 31 |
NCT03019666 |
Recruiting |
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL |
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- (and 5 more...)
|
- Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of any grade 4 or greater suspected adverse reaction
- Occurrence of Grade III or IV acute graft-versus-host disease (aGVHD)
- Occurrence of treatment related mortality (TRM)
- (and 2 more...)
|
24 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03019666 |
2015LS057
MT2015-46 |
|
October 18, 2017 |
April 30, 2019 |
March 31, 2020 |
January 12, 2017 |
June 7, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 32 |
NCT03110432 |
Recruiting |
Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry |
|
- Drug: PCSK9 Inhibitor [EPC]
- Drug: Standard lipid lowering therapy
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- LDL cholesterol goal achievement
- LDL cholesterol reduction
- Number of treatment changes
|
2000 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03110432 |
PERI-DYS |
PERI-DYS |
May 18, 2017 |
December 30, 2020 |
February 16, 2021 |
April 12, 2017 |
August 3, 2017 |
|
- Medizinische Klinik und Poliklinik III
Dresden, Germany
|
|
| 33 |
NCT03313297 |
Recruiting |
Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) |
- Diabetes Mellitus, Type 2
|
- Drug: AZD4017
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Skin 11β-HSD1 activity
- Urinary cortisol / cortisone metabolites
- AZD4017 in plasma
- (and 12 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03313297 |
ED17/93260 |
GC-SHealD |
April 10, 2018 |
September 12, 2018 |
September 28, 2018 |
October 18, 2017 |
May 11, 2018 |
|
- Leeds Teaching Hospitals Trust
Leeds, United Kingdom
|
|
| 34 |
NCT03360435 |
Recruiting |
Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients |
- Bariatric Surgery Candidate
- Vitamin Deficiency
- Mineral Deficiency
|
- Dietary Supplement: Patch MD MultiVitamin Plus patch
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of subjects with deficiencies
- Thiamine
- Pyridoxine
- (and 15 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03360435 |
IRB201701809 |
|
December 15, 2017 |
November 18, 2019 |
November 18, 2019 |
December 4, 2017 |
June 1, 2018 |
|
- University of Florida
Gainesville, Florida, United States
|
|
| 35 |
NCT02537392 |
Recruiting |
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease |
|
- Dietary Supplement: Vitamin B Complex and Folic Acid
- Dietary Supplement: Iron and Folic Acid
- Dietary Supplement: Folic Acid
|
Interventional
|
Not Applicable |
- Health Science Center of Xi’an Jiaotong University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Neonatal pulse oximetry oxygen saturation measured by pulse oximetry
- Incidence of congenital heart disease and the subtypes
- Incidence of birth defects and the subtypes
- (and 9 more...)
|
9374 |
Female |
15 Years to 49 Years (Child, Adult) |
NCT02537392 |
NSFC81230016 |
|
September 2015 |
December 2018 |
June 2019 |
September 1, 2015 |
January 13, 2017 |
|
- Xi'an Jiaotong University College of Medicine
Xi'an, Shaanxi, China
|
|
| 36 |
NCT03582618 |
Not yet recruiting
New |
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma |
- Hepatocellular Carcinoma
- Advanced Cancer
|
- Drug: Sorafenib
- Drug: CVM-1118
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Overall survival (OS)
- Progression-free survival (PFS)
- (and 13 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03582618 |
CVM-004 |
|
July 2018 |
December 2020 |
June 2021 |
July 11, 2018 |
July 11, 2018 |
|
- Charleston Hematology Oncology Associates
Charleston, South Carolina, United States - National Cheng Kung University Hospital
Tainan, Taiwan
|
|
| 37 |
NCT03565536 |
Recruiting
New |
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer |
- Thyroid Cancer, Anaplastic
|
- Drug: Nexavar
- Procedure: operation
- Radiation: External radiation therapy
|
Interventional
|
Phase 2 |
- Fujian Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Thyroglobulin
- CT assessment
- Length of contact surface between tumor and common carotid artery
- (and 6 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03565536 |
UTC-NEXAVAR |
|
May 1, 2018 |
April 30, 2019 |
October 30, 2019 |
June 21, 2018 |
June 21, 2018 |
|
- Fujian Medical University Union Hospital
FuZhou, Fujian, China
|
|
| 38 |
NCT03535259 |
Recruiting |
Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma |
- Hepatocellular Carcinoma, Radiotherapy, Sorafenib
|
- Radiation: concurrent sorafenib and IMRT, followed sorafenib maintenance
|
Interventional
|
Phase 2 |
- Chinese Academy of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MST
- ORR
- TTP
- Rate of III-IV grade adverse events
|
86 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03535259 |
NCC201803020 |
SIRAHCC |
April 20, 2018 |
April 1, 2019 |
April 1, 2021 |
May 24, 2018 |
May 24, 2018 |
|
- Bo Chen
Beijing, Beijing, China
|
|
| 39 |
NCT03518502 |
Recruiting |
Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis |
- Hepatocellular Carcinoma
- Metastasis
|
- Procedure: transarterial chemoembolization (TACE)
- Drug: Sorafenib
|
Interventional
|
Phase 4 |
- Korea University
- Korean Liver Cancer Study Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Time to progression (TTP)
- Progression free survival (PFS)
- Median survival time (MST)
|
130 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03518502 |
2012AS0313 |
|
March 1, 2012 |
February 28, 2020 |
February 28, 2022 |
May 8, 2018 |
May 8, 2018 |
|
- Korea University Ansan Hospital
Ansan, Gyeonggi-do, Korea, Republic of - Soonchunghyang University Bucheon Hospital
Bucheon, Gyeonggi-do, Korea, Republic of - Keimyung University Dongsan Hospital
Daegu, Korea, Republic of - (and 3 more...)
|
|
| 40 |
NCT03412773 |
Recruiting |
Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC |
- Hepatocellular Carcinoma (HCC)
|
- Drug: BGB-A317
- Drug: Sorafenib
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Safety Run-In Substudy[Japan only]: Percentage of patients with adverse events
- Safety Run-In Substudy[Japan only]: Percentage of patients with dose-limiting toxicities (DLT) [Determination of the pivotal Phase 3 dose of BGB-A317 in Japanese patients]
- (and 25 more...)
|
660 |
All |
18 Years and older (Adult, Older Adult) |
NCT03412773 |
BGB-A317-301 |
|
December 28, 2017 |
January 2022 |
May 2022 |
January 26, 2018 |
June 28, 2018 |
|
- St. Jude Heritage Healthcare
Fullerton, California, United States - Ingalls Memorial Hospital
Harvey, Illinois, United States - Healthcare Research Network III, LLC
Tinley Park, Illinois, United States - (and 32 more...)
|
|
| 41 |
NCT03236649 |
Not yet recruiting |
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
- Hepatocellular Carcinoma (HCC)
|
- Drug: Icaritin
- Drug: Sorafenib Tosylate Tablets
|
Interventional
|
Phase 3 |
- Beijing Shenogen Biomedical Co., Ltd
- Chinese Academy of Medical Sciences
- NanJing PLA 81 Hospital
- (and 27 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Time to progress（TTP）
- (and 4 more...)
|
200 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03236649 |
SNG1705ICR-2 |
|
August 30, 2017 |
August 2019 |
August 2019 |
August 2, 2017 |
August 2, 2017 |
|
|
|
| 42 |
NCT03212625 |
Recruiting |
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction |
|
- Drug: Urea Cream 20%
- Drug: Placebos
|
Interventional
|
Phase 4 |
- Korea University Guro Hospital
- Hanmi Pharmaceutical Company Limited
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hand-Foot Skin Reaction(HFSR) prevalence rate on each group
- Event free survival of HFSR
- Severe HFSR prevalence rate
- (and 5 more...)
|
288 |
All |
Child, Adult, Older Adult |
NCT03212625 |
KUGH15337 |
|
January 28, 2016 |
January 31, 2019 |
January 31, 2019 |
July 11, 2017 |
March 7, 2018 |
|
- Korea University Guro Hospital
Seoul, Korea, Republic of
|
|
| 43 |
NCT03178656 |
Recruiting |
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis |
- Portal Vein Tumor Thrombus
|
- Drug: Sorafenib
- Procedure: surgery
|
Interventional
|
Phase 4 |
- Huazhong University of Science and Technology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Prevention
|
- overall survival of 1 year
- overall survival of 3 year
- time to progression
|
54 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT03178656 |
chenxp007 |
|
December 15, 2016 |
April 15, 2018 |
December 15, 2019 |
June 7, 2017 |
December 21, 2017 |
|
- Hepatic surgery center, Tong ji Hospital
Wuhan, Hubei, China
|
|
| 44 |
NCT03140332 |
Recruiting |
Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib. |
- Hepatocellular Carcinoma
- Perfusion Scanner
|
- Other: Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib
|
Interventional
|
Not Applicable |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Scannographic evaluation of tumor response with mRECIST criteria
|
75 |
All |
18 Years and older (Adult, Older Adult) |
NCT03140332 |
PI2016_843_0025 |
HCC-CTPerf |
October 21, 2016 |
October 21, 2019 |
October 21, 2019 |
May 4, 2017 |
May 4, 2017 |
|
- CHU Amiens Picardie
Amiens, Picardie, France
|
|
| 45 |
NCT03097848 |
Recruiting |
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma |
|
- Procedure: RFA
- Drug: Sorafenib
|
Interventional
|
Not Applicable |
- Southwest Hospital, China
- Chengdu PLA General Hospital
- Sichuan Provincial People's Hospital
- (and 11 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival
- Time To Recurrence
- Overall Survival
- (and 3 more...)
|
450 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03097848 |
SWHB 019 |
ESCALATOR |
May 4, 2017 |
December 30, 2018 |
December 31, 2018 |
March 31, 2017 |
May 8, 2017 |
|
- Southwest Hospital
Chongqing, Chongqing, China
|
|
| 46 |
NCT02988440 |
Recruiting |
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients |
|
- Drug: PDR001
- Drug: Sorafenib
|
Interventional
|
Phase 1 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse Events (AEs) as a measure of safety and tolerability
- Pharmacokinetics (PK): Ctrough
- Pharmacokinetics (PK): Cmax
- (and 9 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02988440 |
CPDR001G2101
2016-004131-20 |
|
April 20, 2017 |
December 30, 2018 |
July 18, 2019 |
December 9, 2016 |
November 17, 2017 |
|
- Karmanos Cancer Institute
Detroit, Michigan, United States - Novartis Investigative Site
Montreal, Quebec, Canada - Novartis Investigative Site
Clichy, France - (and 5 more...)
|
|
| 47 |
NCT02867280 |
Recruiting |
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection |
- Hepatocellular Carcinoma
- Recurrence
|
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence free survival
- Time To Recurrence
- Recurrence rate
- (and 3 more...)
|
400 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02867280 |
Sorafenib-MVI |
|
June 2016 |
June 2023 |
June 2023 |
August 15, 2016 |
August 15, 2016 |
|
- Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
|
|
| 48 |
NCT02856126 |
Recruiting |
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC |
|
- Procedure: Hepatic arterial infusion chemotherapy
- Procedure: Transarterial chemoembolization
- Drug: TACE regimen
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Sun Yat-sen University
- Kaiping Central Hospital
- First Affiliated Hospital, Sun Yat-Sen University
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Progress free survival
- Adverse Events
- Number of of Patients developed Adverse Events
|
214 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02856126 |
HCC-S022 |
|
August 2016 |
August 2018 |
August 2018 |
August 4, 2016 |
November 17, 2017 |
|
- Dongguan People's Hospital
Dongguan, Guangdong, China - Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, China - The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China - (and 4 more...)
|
|
| 49 |
NCT02834546 |
Recruiting |
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma |
- Hepatocellular Carcinoma (HCC)
|
- Biological: Sorafenib plasma concentration 4 weeks after treatment initiation
|
Observational
|
|
- University Hospital, Bordeaux
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Adverse events related to Sorafenib needing a dose adjustment or a symptomatic medication
- Adverse events notification
- Radiological response assessed by scan or MRI
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02834546 |
CHUBX 2014/25 |
ACTES |
July 25, 2017 |
November 2018 |
October 2019 |
July 15, 2016 |
November 13, 2017 |
|
- Institut Bergonié
Bordeaux, France - CHU de Limoges
Limoges, France - CHU de Montpellier
Montpellier, France - (and 2 more...)
|
|
| 50 |
NCT02794337 |
Recruiting |
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer |
- Carcinoma, Hepatocellular
|
- Radiation: SBRT
- Procedure: TACE
- Drug: Sorafenib
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- In-field Progression Free Survival
- Cause Specific Survival
- Response assessment after treatment
- (and 2 more...)
|
386 |
All |
18 Years and older (Adult, Older Adult) |
NCT02794337 |
TMC IEC III 91 |
TACE-SBRT |
December 2014 |
January 2019 |
January 2022 |
June 9, 2016 |
June 9, 2016 |
|
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre
Navi Mumbai, Maharashtra, India - Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre
Navi Mumbai, Maharashtra, India
|
|
Create an RSS feed from your search for:
Download the search results for: